Maham Fatima
Wed, June 17, 2026 astatine 8:46 AM CDT 2 min read
In its objective portfolio, Roivant reported affirmative results for IMVT-1402 successful difficult-to-treat rheumatoid arthritis, with further updates expected aboriginal this year. Additionally, brepocitinib received Breakthrough Therapy Designation for cutaneous sarcoidosis, and its commercialized motorboat for dermatomyositis is scheduled for precocious September 2026. Topline information for respective different programs, including studies successful non-infectious uveitis and pulmonary hypertension, are besides anticipated successful H2 2026.
CEO Matt Gline expressed assurance successful the company's momentum, emphasizing the imaginable of their differentiated pipeline to code important diligent needs. With aggregate objective readouts connected the skyline and wide timelines for upcoming launches and proceedings results, Roivant Sciences Ltd. (NASDAQ:ROIV) maintains a beardown strategical trajectory for the remainder of the calendar year.
Roivant Sciences Ltd. (NASDAQ:ROIV) develops and commercializes medicines done a web of subsidiary companies. It acquires oregon in-licenses cause candidates and advances them done objective improvement crossed aggregate therapeutic areas, including immunology, dermatology, and uncommon diseases.
While we admit the imaginable of ROIV arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey connected Google News.

2 hours ago
1




English (CA) ·
English (US) ·
Spanish (MX) ·